Pazdernik VK

Quantitative Health Sciences, Mayo Clinic, Rochester, MN.

7 papers · ORCID

ArticleKetamine

Hepatic Safety of Ketamine and Esketamine for Treatment-Resistant Depression: A Real-World Cohort Study.

Singh B, Leung JG, Pazdernik VK +2

Europe PMC2026
ArticleKetamine

Early suicidal ideation change and suicidality-associated emergency department utilization after ketamine or esketamine treatment in treatment-resistant depression.

Patarroyo-Rodriguez L, Pazdernik VK, Vande Voort JL +2

Europe PMC2026
ArticleKetamine

Ketamine Reduces Suicidality-Associated Emergency Department Utilization in Patients With Treatment-Resistant Depression: A 6-Month Mirror-Image Study.

Patarroyo-Rodriguez L, Pazdernik VK, Vande Voort JL +3

Europe PMC2025
ArticleKetamine

Long-Term Outcomes in Patients With Treatment-Refractory Depression Receiving Intravenous Ketamine and Intranasal Esketamine: An Observational Study.

Singh B, Pazdernik VK, Kung S +1

Europe PMC2025
ArticleKetamine

Baseline perceived stress as a predictor of ketamine/esketamine treatment response in treatment-resistant depression.

Cavalcanti S, Pazdernik VK, Vande Voort JL +2

Europe PMC2025
ArticleKetamine

Treatment-resistant depression patients with baseline suicidal ideation required more treatments to achieve therapeutic response with ketamine/esketamine.

Singh B, Vande Voort JL, Pazdernik VK +2

Europe PMC2024
ArticleKetamine

Efficacy of Ketamine with and without Lamotrigine in Treatment-Resistant Depression: A Preliminary Report.

Joseph B, Nunez NA, Kung S +11

Europe PMC2023